 Phase I/II trial recombinant human granulocyte-macrophage colony-stimulating factor allogeneic bone marrow transplantation Forty-seven patients hematologic neoplasia recombinant human granulocyte-macrophage colony-stimulating factor rhGM-CSF daily infusion allogeneic bone marrow transplantation HLA-identical donors phase I-II dose-escalation trial Dose levels doses toxicity rhGM-CSF negligible patients unacceptable side effects rhGM-CSF different graft-versus-host disease GVHD prophylactic regimens Twenty-seven evaluable patients regimens methotrexate MTX Group absolute neutrophil count median day contrast patients GVHD prophylactic regimens MTX Group II absolute neutrophil count median day Patients Group febrile days initial hospitalizations patients Group II overall incidence severe acute GVHD rhGM-CSF-treated patients similar historical good risk patients rhGM-CSF preliminary data rhGM-CSF unlikely GVHD HLA-identical donor transplants need randomized trials rhGM-CSF allogeneic marrow transplant patients